Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL)
Br J Cancer
.
2021 Jul;125(2):306.
doi: 10.1038/s41416-021-01439-1.
Authors
Francesco Gelsomino
1
,
Marcello Tiseo
2
,
Fausto Barbieri
3
,
Ferdinando Riccardi
4
,
Luigi Cavanna
5
,
Antonio Frassoldati
6
,
Angelo Delmonte
7
,
Lucia Longo
8
,
Claudio Dazzi
9
,
Saverio Cinieri
10
,
Ida Colantonio
11
,
Francesca Sperandi
1
,
Giuseppe Lamberti
1
,
Stefano Brocchi
12
,
Lorenzo Tofani
13
,
Luca Boni
13
,
Andrea Ardizzoni
1
Affiliations
1
Medical Oncology Unit, Policlinico Sant'Orsola-Malpighi, Bologna, Italy.
2
Medical Oncology Unit, Azienda Ospedaliero-Universitaria of Parma, Parma, Italy. mtiseo@ao.pr.it.
3
Medical Oncology Unit, Policlinico of Modena, Modena, Italy.
4
Medical Oncology Unit, Azienda Ospedaliera Cardarelli, Napoli, Italy.
5
Medical Oncology Unit, AUSL of Piacenza, Piacenza, Italy.
6
Medical Oncology Unit, Azienda Ospedaliero-Universitaria of Ferrara, Ferrara, Italy.
7
Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
8
Medical Oncology Unit, AUSL of Modena, Hospital of Carpi, Carpi, Italy.
9
Medical Oncology Unit, AUSL of Romagna, Hospital of Ravenna, Ravenna, Italy.
10
Medical Oncology Unit, Hospital of Brindisi, Brindisi, Italy.
11
Medical Oncology Unit, Hospital of Cuneo, Cuneo, Italy.
12
Radiology Unit, Policlinico Sant'Orsola-Malpighi, Bologna, Italy.
13
Clinical Trial Center, Istituto Toscano Tumori, Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy.
PMID:
34012035
PMCID:
PMC8292309
DOI:
10.1038/s41416-021-01439-1
No abstract available
Publication types
Published Erratum